


PI4748USw

In the Claims:

Please cancel claims 19-24. Please amend Claims 1, 6, 12, 25 and 26 as follows.

Please add new claims 27-36.

1. (Currently Amended) A compound of formula (I)



wherein

R is halogen or C₁₋₄ alkyl;

R₁ is hydrogen or C₁₋₄ alkyl;

R₂ is hydrogen, C₁₋₄ alkyl;

R₃ is hydrogen, C₁₋₄ alkyl;

R₄ is trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;

R₅ is hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C(O)R₆ or S(O)₂R₆;

R₆ is C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is an integer from 1 to 2;

X and Y are independently C(O) or CH₂;

provided that

i) X and Y are not both C(O) and

ii) when X and Y are both CH₂ and p is 1, R₅ is not hydrogen, C₁₋₄ alkyl or C(O)R₆;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously Presented) A compound as claimed in claim 1 wherein m is zero or an integer from 1 to 2.

PI4748USw

3. (Previously Presented) A compound as claimed in claim 1 wherein R₁ is a methyl group.
4. (Previously Presented) A compound as claimed in claim 1 wherein R₂ is a hydrogen atom or a methyl group.
5. (Previously Presented) A compound as claimed in claim 1 wherein R₃ is a hydrogen atom or a methyl group.
6. (Currently Amended) A compound as claimed in claim 1 wherein R₄ is a trifluoromethyl group or halogen (i.e. chlorine).
7. (Previously Presented) A compound as claimed in claim 1 wherein R₅ is hydrogen, methyl cyclopropyl, C(O)CH₃ or S(O)₂CH₃.
8. (Previously Presented) A compound as claimed in claim 1 wherein p is 1.
9. (Previously Presented) A compound as claimed in claim 1 wherein R is at the 2 and/or 4 position in the phenyl ring .
10. (Previously Presented) A compound as claimed in claim 1 wherein n is 2 and the groups R₄ are at the 3 and 5 position in the phenyl ring.
11. (Previously Presented) A compound as claimed in claim 1 wherein
R is fluorine and/or C₁₋₄ alkyl;
R₁ is a methyl group;
R₂ is a hydrogen atom or a methyl group;
R₃ is a hydrogen atom or a methyl group;
R₄ is trifluoromethyl;
R₅ is hydrogen, methyl, cyclopropyl , C(O)CH₃ or S(O)₂CH₃;
m is 1 or 2;
n is 2;

PI4748USw

p is 1.

12. (Currently Amended) A compound selected from
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
- and pharmaceutically acceptable salts and solvates thereof.

PI4748USw


13-15. (Canceled.)

16. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in a mixture with one or more pharmaceutically acceptable carriers or excipients.

17-18. (Canceled.)


19-24. (Canceled)

25. (Currently Amended) A process for preparing a compound according to claim 1, wherein X is CH₂ or C(O) and Y is CH₂, said process comprising reacting a compound of formula (II):



(II)

with compound of formula (III):



(III)


in the presence of a suitable metal reducing agent;

followed where necessary or desired by one or more of the following steps:

- i) removing any protecting group;
- ii) isolating the compound as a salt or a ~~solvent~~ solvate thereof; or
- iii) separating the compound into enantiomers thereof.

26. (Currently Amended) A process for preparing a compound according to claim 1, wherein Y is C(O), said process comprising cyclizing a compound of formula (VII),

PI4748USw



(VII)

wherein P is a nitrogen protecting group and L is a suitable leaving group;
followed where necessary or desired by one or more of the following steps:

- i) removing any protecting group;
- ii) isolating the compound as a salt or a solvate thereof;
- iii) separating the compound into enantiomers thereof.

27. (New) A method for the treatment of a depressive state in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

28. (New) The method according to claim 27 wherein said mammal is man.

29. (New) A method for the treatment of anxiety in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

30. (New) The method according to claim 29 wherein said mammal is man.

31. (New) A method for treatment of emesis in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

32. (New) The method according to claim 31 wherein said mammal is man.

33. (New) A method for treatment of a sleep disorder in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

34. (New) The method according to claim 33 wherein said mammal is man.

PI4748USw

35. (New) A method for treatment of an inflammatory disease of the bladder in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

36. (New) The method according to claim 35 wherein said mammal is man.